SECTOR : Biotech
ENTRY DATE : 2016
BUSINESS : Venture Capital
WEB : coavetx.com
Development of innovative gene therapy products
Coave Therapeutics is a French clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and Central Nervous System diseases. Coave Therapeutics’ next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. The Company is advancing a pipeline of novel therapies targeting rare ocular and brain diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
PRESS RELEASE :
08/07/2016 • Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital